Pterostilbene: a potential therapeutic agent for fibrotic diseases

Area of Science:

• Biochemistry
• Pharmacology
• Pathology

Background:

• Fibrosis, characterized by fibroblast to myofibroblast transformation and excessive extracellular matrix production, is a major contributor to mortality in chronic diseases.
• Pterostilbene (PTS), a natural compound abundant in blueberries and a resveratrol analog, possesses diverse pharmacological properties including antioxidant and anti-inflammatory effects.

Purpose of the Study:

• To comprehensively review the antifibrotic effects of Pterostilbene (PTS) observed both in vivo and in vitro.
• To elucidate the pharmacological mechanisms, pharmacokinetics, and toxicology of PTS in the context of fibrosis treatment.
• To provide insights and strategies for developing PTS as a promising antifibrotic agent.

Main Methods:

• Literature review summarizing existing in vivo and in vitro studies on Pterostilbene's antifibrotic activity.
• Analysis of Pterostilbene's mechanisms of action, including its effects on key signaling pathways.
• Examination of Pterostilbene's pharmacokinetic and toxicological profiles.

Main Results:

• Pterostilbene (PTS) demonstrates efficacy in alleviating myocardial, renal, pulmonary, hepatic, and colon fibrosis.
• PTS inhibits inflammation, oxidative stress, and fibrogenesis through modulation of pathways like TGF-β1/Smads, ROS/Pitx2c/mir-15b, NF-κB, Keap-1/Nrf2, NLRP3, JAK2/STAT3, and Src/STAT3.
• PTS exhibits promising therapeutic potential due to its broad-spectrum antifibrotic activity.

Conclusions:

• Pterostilbene (PTS) is a potent natural compound with significant antifibrotic properties across multiple organs.
• The multifaceted mechanisms of PTS, involving the regulation of critical fibrotic pathways, underscore its therapeutic value.
• Further research into PTS's pharmacokinetics and toxicology is warranted to optimize its clinical application for treating fibrosis.